levistolide A

from Ligusticum glaucescens Franch

Also Known As:

E,Z'-6,6',7,3'a-diligustilide; 1H-5,10c-Ethanonaphtho(1,2-c:7,8-c')difuran-3,10-dione, 1,8-dibutylidene-5,5a,6,7,8,10b-hexahydro-, (5S,8Z,10cS)-

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

1.	Chronic Renal Insufficiency 05/01/2023 - "Levistolide A ameliorates fibrosis in chronic kidney disease via modulating multitarget actions in vitro and in vivo."
2.	Fibrosis (Cirrhosis) 05/01/2023 - "Levistolide A ameliorates fibrosis in chronic kidney disease via modulating multitarget actions in vitro and in vivo."
3.	Breast Neoplasms (Breast Cancer) 04/01/2008 - "The aim of the present study was to investigate the reversing effect of levistolide A (LA) on P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in human breast carcinoma Bcap37/MDR1 cells. " 04/01/2008 - "Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells."
4.	Neoplasms (Cancer) 01/01/2017 - "Levistolide A (LA), a natural compound isolated from the traditional Chinese herb Ligusticum chuanxiong Hort, is used for treating cancer. " 02/01/2019 - "Furthermore, multidrug resistance protein 1 (MDR1) expression in k562/dox cells was downregulated by levistolide A in a dose‑dependent manner, thus suggesting that levistolide A may modulate MDR1 during cancer therapy. "
5.	Cognitive Dysfunction 01/01/2021 - "Levistolide A treatment clearly ameliorated memory deficits and cognitive decline in APP/PS1 Tg mice. "

1.	Member 1 Subfamily B ATP Binding Cassette Transporter
2.	Caspase 3 (Caspase-3)
3.	phthalide

1.	Therapeutics